Related Experiment Videos
Risks of ovulation-induction therapy in systemic lupus erythematosus
D L Huong1, B Wechsler, J C Piette
1Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
British Journal of Rheumatology
|November 1, 1996
Summary
Ovulation-induction therapy can trigger lupus flares and thrombosis in women with systemic lupus erythematosus, especially those with antiphospholipid antibodies. Careful patient selection and monitoring are crucial.
Area of Science:
- Reproductive Endocrinology
- Rheumatology
- Thrombosis
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease.
- Infertility affects many women, sometimes necessitating ovulation-induction therapy.
- Antiphospholipid antibodies are associated with increased thrombotic risk.
Observation:
- Four women with SLE underwent ovulation-induction therapy for infertility.
- Three experienced moderate lupus flares post-therapy.
- One developed severe venous thrombosis (inferior vena cava and renal vein).
- All patients had asymptomatic antiphospholipid antibodies prior to therapy.
Findings:
- Ovulation-induction therapy, potentially via high estrogen levels, can precipitate lupus flares in patients with inactive SLE.
- The presence of antiphospholipid antibodies significantly elevates the risk of thrombotic events during ovulation induction.
- No pregnancies were achieved in this cohort.
Implications:
- Ovulation-induction therapy should be reserved for SLE patients with long-standing inactive disease.
- Prophylactic measures, including increased corticosteroid dosage and anticoagulation (heparin or antiplatelets), are recommended for SLE patients with antiphospholipid antibodies undergoing ovulation induction.
- Enhanced vigilance for lupus flares and thrombosis is warranted in this patient population.